Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Shaji K KumarIstvan MajerSumeet PanjabiRohan MedhekarMarco CampioniMeletios- Athanasios DimopoulosPublished in: Expert review of hematology (2020)
When compared with Kd27 BIW, Kd70 QW is the optimal dose that represents a cost-effective utilization of health care budget with incremental CE ratios well below the accepted willingness-to-pay thresholds in the US.